Evidence map›Paper›PMID 38981932›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Association of CD133, ALDH1, CD117 and OCT4 expression with prognosis of patients with cervical cancer.

Thais Aparecida Gomes Almeida, Odeony Paulo Dos Santos, Vera Aparecida Saddi, Jonathas Xavier Pereira, Helymar da Costa Machado, Megmar Aparecida Santos Carneiro, Henrique Moura de Paula, Rosane Ribeiro Figueiredo-Alves, Luiz Carlos Zeferino, Silvia Helena Rabelo-Santos

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thais Aparecida Gomes AlmeidaInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil.
Odeony Paulo Dos SantosInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil.
Vera Aparecida SaddiPontifical Catholic University of Goiás, Goiânia, Brazil.
Jonathas Xavier PereiraInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil.
Helymar da Costa MachadoCenter for Integral Attention to Women's Health, Campinas, São Paulo, Brazil.
Megmar Aparecida Santos CarneiroInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil.
Henrique Moura de PaulaSchool of Medicine, Federal University of Goiás, Goiânia, Brazil.
Rosane Ribeiro Figueiredo-AlvesSchool of Medicine, Federal University of Goiás, Goiânia, Brazil.
Luiz Carlos ZeferinoDepartment of Obstetrics and Gynecology, State University of Campinas, São Paulo, Brazil.
Silvia Helena Rabelo-SantosInstitute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Brazil. shrabelo@ufg.br.ORCID http://orcid.org/0000-0002-8111-6851

Funding

Fundação de Amparo à Pesquisa do Estado de Goiás 20171026700125900
6 · The paper itself

Abstract

Cancer stem cells (CSC), a small population of neoplastic cells, are associated with worse prognosis. The aim of this study was to evaluate the expression of ALDH1, CD117, CD133 and OCT4; potential markers of CSC; and their associations with the prognosis of women diagnosed with cervical cancer. This retrospective cohort study included 126 women diagnosed with cervical cancer whose biopsies were analyzed by immunohistochemistry. Median values of marked cells were used to define cutoff points for low and high expression. For specific survival, multivariate analyses showed statistical significance for lymph node metastases (HR 8.15; 95% CI 3.00-22.18) and borderline significance for high CD133 expression (p = 0.058). For overall survival, multivariate analyses showed statistical significance for IIA-IVB staging (HR 4.60; 95% CI 1.46-14.56), lymph node metastases (HR 5.13; 95% CI 12.02-13.03) and high CD133 expression (2.67; 95% CI 1.11-6.43). Considering only women with SCC, the same clinicopathological variables were associated with worse specific and overall survival in univariate analyses. However, higher expression of CD 133 (HR 11.10; 95% CI 2.42-50.94 and 6.00; 95% CI 2.02-17.87) and staging IIA-IVB (HR 5.96; 95% CI 1.30-27.34 and HR 12.47; 95% CI 2.45-63.54) respectively impacted negatively specific and overall survival, as multivariate analyses showed. Secondarily, it was observed that ALDH1 expression was associated with adenocarcinoma and CD117 expression with squamous cells carcinoma. Higher expression of CD133 was associated with worse specific and overall survival, indicating that it could have relevance as a clinical marker and therapeutic target.

Indexed as

AC133 AntigenBiomarkers, TumorOctamer Transcription Factor-3Proto-Oncogene Proteins c-kitRetinal DehydrogenaseUterine Cervical NeoplasmsAdultAgedAldehyde Dehydrogenase 1 FamilyFemaleHumansImmunohistochemistryIsoenzymesKaplan-Meier EstimateMiddle AgedNeoplastic Stem CellsAC133 AntigenAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorIsoenzymesOctamer Transcription Factor-3POU5F1 protein, humanPROM1 protein, humanProto-Oncogene Proteins c-kitRetinal DehydrogenaseBiomarkersCancer stem cellsCD133Cervical cancerPrognosisSurvival

Identifiers

PMID38981932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.